Wiedemann Rautenstrauch Syndrome

Wiedemann Rautenstrauch Syndrome

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Wiedemann Rautenstrauch Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • neonatal progeroid syndrome
  • neonatal pseudo-hydrocephalic progeroid syndrome of WRS
  • Rautenstrauch-Wiedemann syndrome

Disorder Subdivisions

  • None

General Discussion

Wiedemann-Rautenstrauch syndrome (WRS), also known as neonatal progeroid syndrome, is a very rare genetic disorder characterized by an aged appearance at birth (old man look) growth delays before and after birth (prenatal and postnatal growth retardation), and deficiency or absence of the layer of fat under the skin (subcutaneous lipoatrophy). It is anticipated that most individuals with WRS have decreased life expectancy. There are few individuals who have lived well in to the teens and afew still live in their 20s. WRS is inherited as an autosomal recessive trait, as several pairs of siblings have been reported in families with unaffected parents.

Symptoms

WRS is characterized by an aged appearance at birth and deficiency or absence of the layer of fat under the skin (subcutaneous lipoatrophy). Progressive neurological deterioration may occur. The specific symptoms may vary from case to case as affected individuals may not have all of the symptoms listed below.



In individuals with WRS, abnormal growth delays may occur before birth (intrauterine growth retardation), particularly during the last three months (third trimester) of fetal development. The growth delays will continue well after birth (postnatal). Patients with WRS also experience poor weight gain, and failure to thrive through their lifetime.In addition, in some cases, affected infants may experience swallowing (dysphagia) and feeding difficulties that may contribute to growth delays and failure to thrive.



Infants with WRS have an aged (progeroid) appearance at birth due to a deficiency or absence of the layer of fat under the skin (subcutaneous lipoatrophy). As a result, the skin may appear unusually thin, fragile, wrinkled, and aged. Certain veins and muscles may be abnormally prominent, particularly those of the forehead. For unknown reasons, as affected infants age, abnormal deposits of fat may accumulate under the skin (subcutaneous) in lower (caudal) areas of the body, particularly around the buttocks, the areas around the genitals and the anus (anogenital area), and the area between the ribs and the hips (flanks). In addition, in infants and children with the disorder, the abdomen may appear unusually large and prominent.



Infants and children with WRS also have distinctive abnormalities of the head and face (craniofacial) . In many cases, the soft spot in the front of the skull (anterior) may be abnormally large and wide, and its closure may be unusually delayed. The fibrous gaps between other bones in the skull (cranial sutures) may also be abnormally wide. In addition, in infants with the disorder, bones of the forehead (frontal bones) and the sides of the skull (parietal bones) are abnormally prominent (frontal and biparietal bossing), while the facial bones are unusually small and underdeveloped (hypoplastic).



Such abnormalities may cause the head to appear unusually large (pseudohydrocephalus). In affected infants and children, distinctive facial abnormalities may include an unusually small mouth (microstomia); a prominent chin, and low-set ears that are abnormally angled toward the back of the head (posteriorly angulated). Facial features typically appear unusually small when compared with the large forehead and sides of the skull. In addition, affected infants may have an unusually small, distinctively "beak-shaped" nose that becomes more pronounced with advancing age.



In most infants and children withWRS, additional craniofacial abnormalities are also present. Affected infants may have two to four front teeth (neonatal incisors) which fall out during the course of early infancy. Subsequent tooth development (dentition) is delayed and impaired. In addition, in infants and children with the disorder, the lower eyelids may droop or turn outward (ectropion), exposing the thin, delicate mucous membranes that line the eyelids as well as a portion of the eyeballs (conjunctivae). An interesting feature in a few cases is that the lower eyelids may cover more than the lower half of the eyeball as if the eyelids are situated higher than expected. Affected infants and children may also have unusually sparse scalp hair, eyebrows, and eyelashes. (hypotrichosis).



Infants and children with WRS may also have distinctive abnormalities affecting the hands, feet, arms, and legs (extremities). The arms and legs are abnormally thin, the hands and feet are disproportionately large; and the fingers and toes are long with unusually small, incompletely developed (atrophic) nails. Recent MRI (magnetic resonance imaging) studies have confirmed the presence of normal amounts of subcutaneous truncal fat, and marked loss of fat from the face and distal extremities. Bone thinning (osteopenia) may predispose to bony fractures. Bone progenitor cell transformation to bone (osteoblasts) and cartilage cells (chondrocytes) are also impaired. The lack of cellular differentiation capacity in WRS patients may be responsible for the clinical appearance and symptoms of this rare disorder.



Most infants and children with the disorder also have varying degrees of mental retardation, which may range from mild to severe. However, a few children have demonstrated near normal mental development. During infancy, affected individuals may begin to experience progressive neurological and neuromuscular abnormalities. In most cases, there are severe delays in the acquisition of skills requiring the coordination of physical and mental activities (psychomotor retardation). In addition, in many cases, infants and children with the disorder lack head control; exhibit diminished muscle tone (hypotonia), and have an impaired ability to coordinate voluntary movements of the chest and abdominal areas (truncal ataxia). For example, they may have difficulty controlling the range of movements during certain muscular actions and may experience rhythmic, involuntary tremors when performing certain movements (intention tremor). Infants and children with the disorder may also experience rapid, involuntary, horizontal movements of the eyes (horizontal nystagmus) and limited clearness (acuity) of vision. Older children may have an unusual high-pitched voice.



In addition, investigators have reported that neurological deterioration observed in a few individuals with WRS may be associated with loss of the myelin sheath from nerve fibers (demyelization) within the white substance of the brain (e.g., pure sudanophilic leukodystrophy). Myelin is a whitish fatty substance that forms a protective wrapping or "sheath" around certain nerve fibers (axons) and serves as an electrical insulator, enabling the effective transmission of nerve impulses. "White substance" within the brain and spinal cord (central nervous system) primarily consists of bundles of myelinated nerve fibers. The majority of cases with WRS did not have leukodystrophy at the age ascertained.



The lack of subcutaneous fat tissue has prompted researchers to compare WRS with generalized lipodystrophy (Berardinelli) syndrome. Laboratory studies, however in those cases examined, have shown no elevation of fasting glucose, lipids, or insulin as would be expected in Berardinelli syndrome. A few patients however, had elevated triglyceride levels.Individuals with WRS may also develop abnormal side-to-side curvature of the spine (scoliosis). In addition, infants and children with WRS are often prone to recurrent respiratory infections, which may result in life-threatening complications.

Causes

WRS is most likely inherited as an autosomal recessive genetic condition. Several siblings with WRS have been reported in unrelated families.



Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person is a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents is 25%. The risk is the same for males and females.



Some individuals with WRS have had parents who were related by blood (consanguineous).



All individuals carry several abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than non-consanguineous parents to carry the same abnormal gene, which increases the risk to have children with a rare recessive genetic disorder.



The specific underlying defect responsible for the disorder remains unknown. However, some researchers suggest that disturbances in bone maturation and hormonal and fatty (lipid) metabolism may play some role.

Affected Populations

WRS is an extremely rare genetic disorder that appears to affect males and females relatively equally. WRS has been observed in various ethnic and racial groups. The disorder was initially described as a distinct entity in 1979 (Wiedemann HR) based upon observation of two unrelated individuals as well as previous reports of two affected sisters in 1977 (Rautenstrauch T). More than 30 cases have been reported in the medical literature to date.

Standard Therapies

Diagnosis

In some cases, growth retardation, macrocephaly, and/or other characteristic findings suggestive of Wiedemann-Rautenstrauch Syndrome may be detected before birth (prenatally) by ultrasound.



In most cases, Wiedemann-Rautenstrauch Syndrome is diagnosed shortly after birth, based upon a thorough clinical evaluation and identification of characteristic physical findings (e.g., small stature, characteristic craniofacial and skeletal malformations, absence or deficiency of subcutaneous fat, etc.). In some cases, specialized tests may also be conducted to detect certain abnormalities potentially associated with the disorder. For example, X-ray studies may reveal and/or confirm wide cranial sutures and/or other abnormalities of cranial bones. In addition, it is possible that computer-assisted tomography (CAT), magnetic resonance imaging (MRI), and/or other specialized tests may reveal widespread loss of the fatty coverings (myelin sheath) on nerve fibers (demyelination) within the white matter of the brain (pure sudanophilic leukodystrophy).



Treatment

The treatment of Wiedemann-Rautenstrauch Syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, specialists who assess and treat disorders of the nervous system (neurologists), physical therapists, and/or other health care professionals may need to systematically and comprehensively plan an affected child's treatment.



Specific therapies for Wiedemann-Rautenstrauch Syndrome are symptomatic and supportive. In some cases, if affected infants and children experience swallowing and feeding difficulties and cannot feed appropriately by mouth, a tube may be surgically inserted into the stomach or a portion of the small intestine (tube feeding) to help provide appropriate nourishment. In addition, affected infants and children should be carefully monitored to help guard against respiratory infections. Genetic counseling will be of benefit for affected individuals and their families.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

TEXTBOOKS

Pivnick EK. Neonatal Progeroid Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:238-39.



Champion RH, et al., eds. Textbook of Dermatology. 5th ed. Cambridge, MA: Blackwell Scientific Publications, Inc.; 1992:1817.



Gorlin RJ, et al., eds. Syndromes of the Head and Neck. 3rd ed. New York, NY: Oxford University Press; 1990:488.



Buyse ML. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications, Inc.; 1990:420-22, 476, 1278-79, 1411-14.



JOURNAL ARTICLES

Arboleda G, Ramirez N, Arboleda H. The neonatal progeroid syndrome (Wiedemann-Rautenstrauch): a model for the study of human aging? Exp Gerontol. 2007 Oct; 42(10):939-43. Epub 2007 Jul 19.



O'Neill B, et al. Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome.. AmJ Med Genet A 2007 July 1;143A(13):1421-30



O'Neill B, Simha V, Kotha V, Garg A. Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. Am J Med Genet A. 2007 Jul 1;143 (13):1421-30.



Jäger M et al. In vitro osteogenic differentiation is affected in Wiedemann-Rautenstrauch-Syndrome (WRS). In Vivo.2005 Sept-Oct;19(5):831-6.



Arboleda H and Arboleda G. Follow-up study of Wiedemann-Rautenstrauch syndrome: long term survival and comparison with Rautenstrauch's patient "G". Birth Defects Res A Clin Mol Teratol. 2005 Aug;73(8):562-8.



Hoppen T et al. Siblings with neonatal progeroid syndrome (Wiedemann-Rautenstauch). Klin Padiatr. 2004 Mar-Apr;216(2):70-1.



Cao H and Hegele RA. LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedeman-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet. 2003; Vol 48,Number 5,271-274.



Thorey F, et al. Kyphoscoliosis in Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome). Z Orthop Ihre Grenzgeb. 2003;141:341-4.



Korniszewski L, et al., Wiedemann-Rautenstrauch (neonatal progeroid) syndrome: new case with normal telomere length in skin fibroblasts. Am J Med Genet. 2001;103:144-8.



Korniszewski L et al. Wiedemann-Rautenstrauch (neonatal progeria) syndrome: New case with normal telomere length in skin fibroblasts. Am J Med Genet. 2001: October 1;103(2): 144-148.



Pivnick EK, et al. Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. Am J Med Genet. 2000;90:131-40.



Hoppen T, et al. Neonatal progeroid syndrome (Wiedemann-Rautenstrauch syndrome): case report and review of the literature. Klin Padiatr. 2000;212:71-76.



Stoll C, et al. Wiedemann-Rautenstrauch syndrome. A case report and review of the literature. Genet Couns. 1998;9:119-24.



Courtens W, et al. A probable case of Wiedemann-Rautenstrauch syndrome or neonatal progeroid syndrome and review of the literature. Clin Dysmorphol. 1997;6:219-27.



Arboleda H, et al. Wiedemann-Rautenstrauch neonatal progeroid syndrome: report of three new patients. J Med Genet. 1997;34:433-37.



Bitoun P, et al. The Wiedemann-Rautenstrauch neonatal progeroid syndrome: a case report and review of the literature. Clin Dysmorphol. 1995;4:239-45.



Rautenstrauch T, et al. Neonatal progeroid syndrome (Wiedemann-Rautenstrauch). A follow-up study. Klin Padiatr. 1994;206:440-43.



Mazzarello P, et al. Enzymes of DNA metabolism in a patient with the Wiedemann-Rautenstrauch progeroid syndrome. Ann N Y Acad Sci. 1992;663:440-41.



Castineyra G, et al. Two sibs with Wiedemann-Rautenstrauch syndrome: possibilities of prenatal diagnosis by ultrasound. J Med Genet. 1992;29:434-36.



Toriello HV. Wiedemann-Rautenstrauch syndrome. J Med Genet. 1990;27:256-57.



Hagadorn JI, et al. Neonatal progeroid syndrome: more than one disease? Am J Med Genet. 1990;35:91-94.



Rudin C, et al. The neonatal pseudo-hydrocephalic progeroid syndrome (Wiedemann-Rautenstrauch). Report of a new patient and review of the literature. Eur J Pediatr. 1988;147:433-38.



Martin JJ, et al. The Wiedemann-Rautenstrauch or neonatal progeroid syndrome. neuropathological study of a case. Neuropediatrics. 1984;15:43-48.



Devos EA, et al. The Wiedemann-Rautenstrauch or neonatal progeroid syndrome. Report of a patient with consanguineous parents. Eur J Pediatr. 1981;136:245-48.



Wiedemann HR. An unidentified neonatal progeroid syndrome: follow-up report. Eur J Pediatr. 1979;130:65-70.



Rautenstrauch T, et al. Progeria: a cell culture study and clinical report of familial incidence. Eur J Pediatr. 1977;124:101-11.

Resources

Progeria Research Foundation, Inc.

2 Bourbon Street

Suite 208

Peabody, MA 01960

USA

Tel: (978)535-2594

Fax: (978)535-5849

Email: info@progeriaresearch.org

Internet: http://www.progeriaresearch.org



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981

Internet: http://www.ninds.nih.gov/



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.